Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. (October 2019)

• Record Type: Journal Article
• Authors: Fissolo, Nicolas; Cervera-Carles, Laura; Villar Guimerans, Luisa María; Lleó, Alberto; Clarimón, Jordi; Drulovic, Jelena; Dujmovic, Irena; Voortman, Margarete; Khalil, Michael; Gil, Elia; Navarro, Laura; Álvarez-Cermeño, Jose Carlos; Montalban, Xavier; Comabella, Manuel
• Is Part Of: Multiple sclerosis. Volume 25:Number 11(2019)
• Page Start: 1535
• Page End: 1538
• Publication Date: 2019-10
• Subjects: Mitochondrial DNA -- cerebrospinal fluid -- multiple sclerosis -- droplet digital PCR; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458518786055
• Languages: English
• ISSNs: 1352-4585

Abstract

The role of cerebrospinal fluid (CSF) mitochondrial DNA (mtDNA) levels as biomarker in multiple sclerosis (MS) is unknown. We determined CSF mtDNA levels in a cohort of 237 individuals, including patients with MS and clinically isolated syndrome (CIS), inflammatory and non-inflammatory neurological controls, and cognitively healthy controls (HC). mtDNA concentration was measured by droplet digital polymerase chain reaction. CSF mtDNA levels were increased in all pathological conditions compared with HC, though no differences were observed between relapse-onset and progressive MS clinical forms, CIS patients and neurological controls. These findings do not support the determination of CSF mtDNA levels as a useful biomarker in MS clinical practice.